Skip to search formSkip to main contentSkip to account menu

CH5424802

National Institutes of Health

Related topics

Related topics

5 relations
AF802

Broader (2)

CarbazolesPiperidines

Narrower (2)

RO5424802alectinib

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2018
Review
2018
Phase II Trial of CH5424802 (alectinib hydrochloride) for Recurrent or Refractory ALK-Positive Anaplastic Large Cell Lymphoma
Introduction: Anthracycline-based combination chemotherapy is a standard first-line treatment for anaplastic lymphoma kinase… 
2017
2017
Phase II trial of CH5424802 (alectinib hydrochloride) for recurrent or refractory ALK-positive anaplastic large cell lymphoma: study protocol for a non-randomized non-controlled trial
ABSTRACT Currently, a standard therapy has not been established for recurrent or refractory anaplastic lymphoma kinase-positive… 
2015
2015
Abstract 759: Metformin enhances the benefit of ALK inhibitors in ALK translocation-positive non-small cell lung cancer cells
Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA Background: Crizotinib is an effective tyrosine… 
Review
2013
Review
2013
Journey of the ALK-inhibitor CH5424802 to phase II clinical trial
The anaplastic lymphoma kinase (ALK) receptor tyrosine kinase represents a potential therapeutic target. Specially, a variety of… 
2013
2013
A phase I/II study with a highly selective ALK inhibitor CH5424802 in ALK-positive non-small cell lung cancer (NSCLC) patients: Updated safety and efficacy results from AF-001JP.
8033 Background: Anaplastic lymphoma kinase (ALK) is a constitutively activated tyrosine kinase in a subset of NSCLC with ALK… 
2013
2013
A selective ALK inhibitor in ALK-rearranged patients.
2013
2013
Evolving Management with Molecular-Targeted and Bone-Targeted Medicine in Patients with Advanced Non-Small Cell Lung Cancer
In the field of advanced non-small cell lung cancer (NSCLC), the driver mutations such as epidermal growth factor receptor (EGFR… 
2013
2013
Abstract 2192: A novel mechanism of EML4-ALK rearrangement in a patient-derived cell line and its tumor growth inhibition by an ALK inhibitor CH5424802.
Purpose: EML4-ALK is a driver oncogene in non-small cell lung cancer (NSCLC) and has been developed into a promising molecular… 
2011
2011
Abstract 3593: Generation of a potent and selective inhibitor of ALK, CH5424802, showing superior oral bioavailability, PK profile and in vivo efficacy
Anaplastic lymphoma kinase (ALK) is a tyrosine kinase that is constitutively activated in some cancers, due to gene alterations… 
2011
2011
Abstract 3559: A new selective ALK inhibitor CH5424802 shows potent efficacy against ALK-positive cancers including the gatekeeper mutant-driven tumors
The recent development of targeted protein kinase inhibitors has provided new opportunity in cancer treatment. However, certain… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)